Align Technology's EPS (Basic) for the
three
months ended in Dec. 2024 was $1.39.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was $5.62.
During the past 12 months, Align Technology's average EPS without NRIGrowth Rate was 8.40% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was -1.30% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -2.00% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 20.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Align Technology's highest 3-Year average EPS without NRI Growth Rate was 232.90% per year. The lowest was -27.30% per year. And the median was 22.80% per year.
Align Technology EPS (Diluted) Historical Data
The historical data trend for Align Technology's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Align Technology's EPS (Diluted)
For the Medical Instruments & Supplies subindustry, Align Technology's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Align Technology's PE Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Align Technology's PE Ratio distribution charts can be found below:
* The bar in red indicates where Align Technology's PE Ratio falls into.
Align Technology EPS (Diluted) Calculation
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Align Technology's Diluted EPS for the fiscal year that ended in Dec. 2024 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.61
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Align Technology EPS (Diluted) Related Terms
Thank you for viewing the detailed overview of Align Technology's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALGN has been successfully added to your 